Clinical Trials

SL-172154 SIRPα-Fc-CD40L


Overview

Two Phase 1 clinical trials are expected to commence in 2020 utilizing the SL-172154 compound. The first clinical trial will explore intravenous administration of SL-172154 in patients with ovarian, fallopian tube, and primary peritoneal cancer. The second clinical trial will enroll patients with squamous cell carcinoma of the skin and head and neck who will receive SL-172154 via intratumoral administration.

SL-172154 Clinical Trial Locations


United States, California
  • Santa Monica, California, United States, 90404
United States, Massachusetts
  • Boston, Massachusetts, United States, 02215
United States, Michigan
  • Grand Rapids, Michigan, United States, 49546
United States, Oklahoma
  • Oklahoma City, Oklahoma, United States, 73104

Healthcare Professionals: To learn more about Shattuck’s trials, email clinicaltrials@shattucklabs.com.

Patients and Caregivers: Talk to your doctor if you are interested in learning more about Shattuck clinical trials.

Investigational: These molecules and their uses are investigational and have not been approved for use anywhere in the world.